Comprehensive Program for Hereditary Transthyretin Amyloidosis

Comprehensive Program for Hereditary Transthyretin Amyloidosis

The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.

Inclusion Criteria:

-Participants with a pathogenic variant of the TTR gene (Hereditary Amyloidosis)

Exclusion Criteria:

• wild-type TTR amyloidosis